Treatment of Self Harm Scars With Fraxel Laser
Sponsor
Darius Mehregan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05363969
Collaborator
(none)
10
17
Study Details
Study Description
Brief Summary
Treatment of self harm scars with fractionated laser.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Fractionated resurfacing lasers have been shown to be useful for scars including acne scars, burns scars and striae. We will treat self harm scars with 3 to 4 treatments using a "Fraxel" fractionated laser. Patients will be screened to ensure they are not actively engaged in self harm behaviors.
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
10 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Self Harm Scars With Fraxel Laser
Anticipated Study Start Date
:
Jul 1, 2022
Anticipated Primary Completion Date
:
Jul 1, 2023
Anticipated Study Completion Date
:
Dec 1, 2023
Outcome Measures
Primary Outcome Measures
- Clinical improvement of scars [6 months]
Patients will be assessed with pre and post treatment photography. Photographs will be taken at baseline and 1 month after the final treatment. After the final treatment both the investigator and patients will rate appearance of scarring as "worsened", "unchanged" or "improved" as compared to baseline.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Self harm scars
Exclusion Criteria:
- Active self harm behaviors
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Darius Mehregan
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Darius Mehregan,
Chairman Dept of Dermatology,
Wayne State University
ClinicalTrials.gov Identifier:
NCT05363969
Other Study ID Numbers:
- IRB-21-06-3672
First Posted:
May 6, 2022
Last Update Posted:
May 6, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: